Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA. Montaner JS, et al. Among authors: smaldone l. Ann Intern Med. 1995 Oct 15;123(8):561-71. doi: 10.7326/0003-4819-123-8-199510150-00001. Ann Intern Med. 1995. PMID: 7677296 Clinical Trial.
Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
Montaner JS, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, et al. Montaner JS, et al. Among authors: smaldone l. J Acquir Immune Defic Syndr (1988). 1994 Sep;7(9):924-30. J Acquir Immune Defic Syndr (1988). 1994. PMID: 7519674
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH, Smaldone L. Spruance SL, et al. Among authors: smaldone l. Ann Intern Med. 1994 Mar 1;120(5):360-8. doi: 10.7326/0003-4819-120-5-199403010-00002. Ann Intern Med. 1994. PMID: 7905722 Clinical Trial.
Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients.
Rozencweig M, McLaren C, Beltangady M, Ritter J, Canetta R, Schacter L, Kelley S, Nicaise C, Smaldone L, Dunkle L, et al. Rozencweig M, et al. Among authors: smaldone l. Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S570-5. doi: 10.1093/clinids/12.supplement_5.s570. Rev Infect Dis. 1990. PMID: 2166965 Clinical Trial.
Design and implementation of the stavudine parallel-track program.
Anderson RE, Dunkle LM, Smaldone L, Adler M, Wirtz C, Kriesel D, Cross A, Martin RR. Anderson RE, et al. Among authors: smaldone l. J Infect Dis. 1995 Mar;171 Suppl 2:S118-22. doi: 10.1093/infdis/171.supplement_2.s118. J Infect Dis. 1995. PMID: 7861016 Clinical Trial.
Overview of hormonal therapy in advanced breast cancer.
Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L. Schacter LP, et al. Among authors: smaldone l. Semin Oncol. 1990 Dec;17(6 Suppl 9):38-46. Semin Oncol. 1990. PMID: 2148026
Megestrol acetate: clinical experience.
Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L. Schacter L, et al. Among authors: smaldone l. Cancer Treat Rev. 1989 Mar;16(1):49-63. doi: 10.1016/0305-7372(89)90004-2. Cancer Treat Rev. 1989. PMID: 2471590 Review.
23 results